These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 28142305)

  • 41. Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine.
    Dahan A; van Dam CJ; Niesters M; van Velzen M; Fossler MJ; Demitrack MA; Olofsen E
    Anesthesiology; 2020 Sep; 133(3):559-568. PubMed ID: 32788558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain.
    Gan TJ; Wase L
    Drugs Today (Barc); 2020 Apr; 56(4):269-286. PubMed ID: 32309822
    [TBL] [Abstract][Full Text] [Related]  

  • 43. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
    Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
    Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
    Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of repeated morphine on intracranial self-stimulation in male rats in the absence or presence of a noxious pain stimulus.
    Miller LL; Altarifi AA; Negus SS
    Exp Clin Psychopharmacol; 2015 Oct; 23(5):405-14. PubMed ID: 26375515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine.
    Zadina JE; Nilges MR; Morgenweck J; Zhang X; Hackler L; Fasold MB
    Neuropharmacology; 2016 Jun; 105():215-227. PubMed ID: 26748051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oliceridine (TRV130), a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model.
    Fossler MJ; Sadler BM; Farrell C; Burt DA; Pitsiu M; Skobieranda F; Soergel DG
    J Clin Pharmacol; 2018 Jun; 58(6):750-761. PubMed ID: 29412458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics.
    Schmid CL; Kennedy NM; Ross NC; Lovell KM; Yue Z; Morgenweck J; Cameron MD; Bannister TD; Bohn LM
    Cell; 2017 Nov; 171(5):1165-1175.e13. PubMed ID: 29149605
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists.
    Gillis A; Gondin AB; Kliewer A; Sanchez J; Lim HD; Alamein C; Manandhar P; Santiago M; Fritzwanker S; Schmiedel F; Katte TA; Reekie T; Grimsey NL; Kassiou M; Kellam B; Krasel C; Halls ML; Connor M; Lane JR; Schulz S; Christie MJ; Canals M
    Sci Signal; 2020 Mar; 13(625):. PubMed ID: 32234959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Site and mechanism of morphine tolerance in the gastrointestinal tract.
    Akbarali HI; Inkisar A; Dewey WL
    Neurogastroenterol Motil; 2014 Oct; 26(10):1361-7. PubMed ID: 25257923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.
    Crowley RS; Riley AP; Sherwood AM; Groer CE; Shivaperumal N; Biscaia M; Paton K; Schneider S; Provasi D; Kivell BM; Filizola M; Prisinzano TE
    J Med Chem; 2016 Dec; 59(24):11027-11038. PubMed ID: 27958743
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sex differences in opioid antinociception.
    Bartok RE; Craft RM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):769-78. PubMed ID: 9262340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability.
    Negus SS; Schrode K; Stevenson GW
    Exp Clin Psychopharmacol; 2008 Oct; 16(5):386-99. PubMed ID: 18837635
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity.
    Altarifi AA; Rice KC; Negus SS
    J Pharmacol Exp Ther; 2015 Feb; 352(2):208-17. PubMed ID: 25406170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The μ-opioid receptor-mediated G
    Xia J; Li X; Zhu H; Zhou X; Chen J; Li Q; Li S; Chu H; Dong M
    Eur J Pharmacol; 2024 Mar; 966():176333. PubMed ID: 38278466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein kinase C-mediated acute tolerance to peripheral mu-opioid analgesia in the bradykinin-nociception test in mice.
    Inoue M; Ueda H
    J Pharmacol Exp Ther; 2000 May; 293(2):662-9. PubMed ID: 10773042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.
    Singla N; Minkowitz HS; Soergel DG; Burt DA; Subach RA; Salamea MY; Fossler MJ; Skobieranda F
    J Pain Res; 2017; 10():2413-2424. PubMed ID: 29062240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H.
    Gallantine EL; Meert TF
    Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):419-27. PubMed ID: 18699797
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Direct involvement of the supraspinal phosphoinositide 3-kinase/phospholipase C gamma 1 pathway in the mu-opioid receptor agonist-induced supraspinal antinociception in the mouse].
    Narita M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Jun; 23(3):121-8. PubMed ID: 12884752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.